Prediction and prevention of sudden cardiac death in heart failure
暂无分享,去创建一个
[1] R. Maestri,et al. Short-Term Heart Rate Variability Strongly Predicts Sudden Cardiac Death in Chronic Heart Failure Patients , 2003, Circulation.
[2] J. Oss,et al. PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .
[3] K. Lee,et al. Prediction of Long-Term Outcomes by Signal-Averaged Electrocardiography in Patients With Unsustained Ventricular Tachycardia, Coronary Artery Disease, and Left Ventricular Dysfunction , 2001, Circulation.
[4] M. Yokoyama,et al. Onset heart rate of microvolt-level T-wave alternans provides clinical and prognostic value in nonischemic dilated cardiomyopathy. , 2002, Journal of the American College of Cardiology.
[5] M. Keller,et al. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. , 1997, The New England journal of medicine.
[6] B. Pitt,et al. Eplerenone , a Selective Aldosterone Blocker , in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .
[7] J. Bigger,et al. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. , 1997, The New England journal of medicine.
[8] E. Caref,et al. Risk stratification for arrhythmic events in patients with nonischemic dilated cardiomyopathy and nonsustained ventricular tachycardia: role of programmed ventricular stimulation and the signal-averaged electrocardiogram. , 1994, Journal of the American College of Cardiology.
[9] Fesc,et al. Efficacy and safety of d,l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest. , 1997, Journal of the American College of Cardiology.
[10] CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.
[11] A. Moss,et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. , 1996, The New England journal of medicine.
[12] D. Delurgio,et al. Cardiac resynchronization in chronic heart failure. , 2002, The New England journal of medicine.
[13] Panos Vardas,et al. Update of the guidelines on sudden cardiac death of the European Society of Cardiology. , 2003, European heart journal.
[14] H. Dargie,et al. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial , 2001, The Lancet.
[15] Fach,et al. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.
[16] S. Hohnloser,et al. Prevalence, characteristics and prognostic value during long-term follow-up of nonsustained ventricular tachycardia after myocardial infarction in the thrombolytic era. , 1999, Journal of the American College of Cardiology.
[17] J. Schwartz,et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. , 1996, Circulation.
[18] J. Mason,et al. Sudden death in idiopathic dilated cardiomyopathy. , 1987, Annals of internal medicine.
[19] H. Doval,et al. Randomised trial of low-dose amiodarone in severe congestive heart failure , 1994, The Lancet.
[20] M. Nieminen,et al. Clinical applications of B-type natriuretic peptide (BNP) testing. , 2003, European heart journal.
[21] K. Kuck,et al. Primary Prevention of Sudden Cardiac Death in Idiopathic Dilated Cardiomyopathy: The Cardiomyopathy Trial (CAT) , 2002, Circulation.
[22] K. Lee,et al. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators. , 2000, The New England journal of medicine.
[23] R. Berger,et al. B-Type Natriuretic Peptide Predicts Sudden Death in Patients With Chronic Heart Failure , 2002, Circulation.
[24] M. Anastasiou-Nana,et al. Relation of dispersion of QRS and QT in patients with advanced congestive heart failure to cardiac and sudden death mortality. , 2000, The American journal of cardiology.
[25] K. Bailey,et al. Failure of signal-averaged electrocardiography with use of time-domain variables to predict inducible ventricular tachycardia in patients with conduction defects. , 1995, Mayo Clinic proceedings.
[26] B. Pitt,et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.
[27] M. Malik,et al. QT Dispersion Has No Prognostic Information for Patients With Advanced Congestive Heart Failure and Reduced Left Ventricular Systolic Function , 2001, Circulation.
[28] S. Dubner,et al. Nonsustained ventricular tachycardia in severe heart failure. Independent marker of increased mortality due to sudden death. GESICA-GEMA Investigators. , 1996, Circulation.
[29] Bigger Jt,et al. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery , 1997 .
[30] E. Ambrosioni,et al. Do ACE inhibitors or angiotensin II antagonists reduce total mortality and arrhythmic mortality? A critical review of controlled clinical trials , 2002, Current opinion in cardiology.
[31] M. J. Hurst,et al. The Heart, Arteries and Veins , 1974 .
[32] Hugh Calkins,et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. , 2004, The New England journal of medicine.
[33] K. Kuck,et al. Primary Prevention of Sudden Cardiac Death in Idiopathic Dilated Cardiomyopathy: The Cardiomyopathy Trial (CAT) , 2002, Circulation.
[34] A. Adgey,et al. Initiation of ventricular fibrillation outside hospital in patients with acute ischaemic heart disease. , 1982, British heart journal.
[35] R Lazzara,et al. Recording from the body surface of arrhythmogenic ventricular activity during the S-T segment. , 1978, The American journal of cardiology.
[36] D. DeMets,et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. , 2004, The New England journal of medicine.
[37] David O. Martin,et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. , 2002, JAMA.
[38] S. Saksena,et al. Device Use Patterns and Clinical Outcome of Implantable Cardioverter Defibrillator Patients with Moderate and Severe Impairment of Left Ventricular Function , 1993, Pacing and clinical electrophysiology : PACE.
[39] A. Louis,et al. Update of clinical trials from the American College of Cardiology 2003. EPHESUS, SPORTIF‐III, ASCOT, COMPANION, UK‐PACE and T‐wave alternans , 2003, European journal of heart failure.
[40] F. Morady,et al. Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia--AMIOVIRT. , 2003, Journal of the American College of Cardiology.
[41] K. Lee,et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. , 1999, The New England journal of medicine.
[42] W. Grimm,et al. Implantable defibrillator event rates in patients with idiopathic dilated cardiomyopathy, nonsustained ventricular tachycardia on Holter and a left ventricular ejection fraction below 30%. , 2002, Journal of the American College of Cardiology.
[43] P. Denes,et al. Definition of the best prediction criteria of the time domain signal-averaged electrocardiogram for serious arrhythmic events in the postinfarction period. The Cardiac Arrhythmia Suppression Trial/Signal-Averaged Electrocardiogram (CAST/SAECG) Substudy Investigators. , 1995, Journal of the American College of Cardiology.
[44] S. Fisher,et al. Nonsustained ventricular tachycardia in severe heart failure. , 1997, Circulation.
[45] P C Deedwania,et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. , 1995, The New England journal of medicine.
[46] Douglas L Packer,et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.
[47] R. Virmani,et al. Sudden cardiac death. , 1987, Human pathology.
[48] G. Fonarow,et al. Improved survival in patients with nonischemic advanced heart failure and syncope treated with an implantable cardioverter-defibrillator. , 2000, The American journal of cardiology.
[49] Milton Packer,et al. Cardiac resynchronization in chronic heart failure. , 2002, The New England journal of medicine.
[50] W. Stevenson,et al. Syncope in advanced heart failure: high risk of sudden death regardless of origin of syncope. , 1993, Journal of the American College of Cardiology.
[51] S. Hohnloser,et al. Predictive value of T-wave alternans for arrhythmic events in patients with congestive heart failure , 2000, The Lancet.
[52] F. Morady,et al. Outcome of patients with nonischemic dilated cardiomyopathy and unexplained syncope treated with an implantable defibrillator. , 1999, Journal of the American College of Cardiology.
[53] S. Hohnloser,et al. T-wave alternans negative coronary patients with low ejection and benefit from defibrillator implantation , 2003, The Lancet.
[54] M Gent,et al. Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. , 2000, Circulation.
[55] M. Borggrefe,et al. QRS duration: a simple marker for predicting cardiac mortality in ICD patients with heart failure , 2003, Heart.